title: Active acute leukaemia: should transplant be offered to all patients?
abstract: The probability of achieving long term remission for patients with refractory acute leukaemia is very low. Allogeneic stem cell transplantation (SCT) is offered to these patients in order to improve their dismal outcome. We retrospectively analyzed 361 acute leukaemia patients, who underwent allogeneic SCT in the Hadassah's bone marrow transplantation department between the years 2005 and 2012 and identified 84 patients with active leukaemia at transplantation. Median age was 34 years. Sixty four patients were diagnosed with acute myeloid leukaemia (AML), 18 patients with acute lymphoblastic leukaemia and two with biphenotypic leukaemia. The majority of patients were diagnosed with de-novo AML and transplanted at relapse. In the surviving patients, median follow up was 15 months. One year OS was 20%. At time of last follow up, 13 patients were alive (15.5%): ten patients with AML and two patients with acute lymphoblastic leukaemia. In the univariate analysis, factors associated with significantly better overall survival were as follows: matched unrelated donor (p = 0.006), matched donor (p = 0.014) and occurrence of acute graft-versus-host disease (aGVHD) (p = 0.019). Karnofsky performance score at SCT and occurrence of cGVHD were found to be borderline significant. Only matched unrelated donor and aGVHD were found to affect overall survival significantly in the multivariate analysis. Other than performance score at SCT, none of the pretransplant patients' characteristics were found to influence survival. In conclusion, as none of the pretransplant characteristics were found to influence the ability to select the patients that will benefit from HSC transplantation, this work supports offering HSCT to all active leukaemia eligible patients with reasonable performance status. Copyright © 2016 John Wiley & Sons, Ltd.
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Batia
authors.initials: B
authors.lastname: Avni
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Michael Y
authors.initials: MY
authors.lastname: Shapira
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Igor B
authors.initials: IB
authors.lastname: Resnick
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Polina
authors.initials: P
authors.lastname: Stepensky
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Reuven
authors.initials: R
authors.lastname: Or
authors.affiliation: Hadassah-Hebrew University Medical Center, Bone Marrow Transplantation and Cancer Immunotherapy Department, Jerusalem, Israel.
authors.forename: Sigal
authors.initials: S
authors.lastname: Grisariu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods*; D055815:Young Adult
keywords: active leukaemia; allogeneic hematopoietic stem cell transplantation; refractory acute leukaemia